A radiologist uses a magnifying glass to check mammograms for breast cancer. File
| Photo Credit: AP

Apple has been accused of exposing users to cancer in a new lawsuit filed in the US that claims that the tech giant’s Watch bands contain high levels of toxic chemicals. According to Daily Mail, the lawsuit claims that Apple’s “Ocean,” “Nike Sport,” and regular “Sport” Watch bands contain high levels of perfluoroalkyl and polyfluoroalkyl substances (PFAS), commonly known as “forever chemicals,” which have been linked to a range of health problems. PFAS chemicals are known for their ability to persist in the human body and environment, earning them their nickname. 

According to the Daily Mail, the lawsuit stems from a recent study on 22 watch bands from various companies in the US. The research found that 15 of the 22 contained harmful PFAS chemicals; among these watches, some were made by Apple. 

The lawsuit, filed in California on Tuesday, specifically alleges that the Sport Band, the Ocean Band and the Nike Sport Band that ships with Nike-branded Apple Watches contain high levels of PFAS. It also alleges that Apple knowingly and willfully did not inform consumers which products contain harmful PFAS, even though the Apple Watch is marketed as a health-promoting device. 

“Instead, in respect of watches, (Apple) continues to hide the existence of PFAS at the point of purchase and otherwise,” the lawsuit states. “(Apple) could have avoided the unreasonable safety and environmental hazard with available manufacturing alternatives, and its failure to do so while continuing to promise consumers health, wellness, and sustainability is unlawful, unfair, and fraudulent under consumer protection laws,” it continues.

Also Read | Colombian President’s Daughter Mocks Trump In Tariff Clash: “For Every Colombian Deported, We Will…”

The lawsuit seeks class certification, which is like a mini-trial in which the allegations are examined and argued by each side’s attorneys. It also seeks an injunction to halt the sale of the alleged PFAS-containing watch bands and monetary penalties, the outlet reported. 

Meanwhile, in a statement to Daily Mail, Apple claimed that its Watch bands are safe for users to wear. “In addition to our own testing, we also work with independent laboratories to conduct rigorous testing and analysis of the materials used in our products, including Apple Watch bands,” the tech giant said. 

Apple has also long claimed that its Watch bands are made from fluoroelastomer, a synthetic rubber that contains fluorine but not harmful PFAS chemicals. The company asserts that fluoroelastomer is safe and thoroughly tested to meet health standards.

More and more countries are legalising voluntary assisted dying. This lets a doctor, or sometimes a nurse practitioner, give life-ending medication to an eligible person who requests it.

As of 2023, 282 million people lived in regions where voluntary assisted dying is legal. Jurisdictions such as the Netherlands, Belgium and Oregon have had these laws in place for decades. Other countries, including Canada, Spain, New Zealand and Australia, have passed reforms more recently.

The trend towards legalisation is continuing. Several countries are actively considering this issue, with strong public support. In November, the United Kingdom’s House of Commons supported an assisted dying bill for the first time, after years of failed attempts.

Debates about voluntary assisted dying are often highly polarised. Understanding the factors driving assisted dying is essential for evidence-based debates and for improving care for people with serious conditions.

In a recent study, we examined data from people accessing voluntary assisted dying in 20 jurisdictions around the world. In particular we looked at what diseases they had.

What Are The Rules?

The legal rules for voluntary assisted dying vary by country (and what it’s called differs too).

In countries including Australia and New Zealand, voluntary assisted dying is available only to people who are terminally ill. For example, in Australia a person must have an advanced, progressive condition that is generally expected to cause death within a certain time frame (6 to 12 months, depending on the state).

Countries such as the Netherlands, Spain and Canada also allow access for eligible people suffering from non-terminal conditions. Canada allows voluntary assisted dying for those who are suffering intolerably from “grievous and irremediable” conditions. While a person’s condition doesn’t have to be terminal, extra safeguards apply when a person’s natural death is not “reasonably foreseeable”.

That said, voluntary assisted dying for non-terminal conditions remains rare. In 2023, 95.9% of people who accessed voluntary assisted dying in Canada had a reasonably foreseeable natural death.

Who can administer the medication also varies. In the United States and Switzerland, people must take the medication themselves, usually by swallowing a liquid (known as “self-administration”).

In Québec, Canada, physicians or nurse practitioners must administer it, which usually happens intravenously. In several jurisdictions, including Australia, both self-administration and practitioner administration are available.

Our Research

With an international team of researchers, we looked at the role disease plays in voluntary assisted dying. We analysed publicly available data from 20 jurisdictions in eight countries between 1999 and 2023.

Overall, most people who accessed voluntary assisted dying had cancer (66.5% of cases). Neurological diseases were the second most common (8.1%), followed by heart (6.8%) and lung (4.9%) conditions.

We also looked at what proportion of people with each disease accessed voluntary assisted dying versus dying by other means. Even though voluntary assisted dying rates and eligibility criteria vary by location, the rates for specific diseases were surprisingly consistent across regions and time periods.

For example, people with amyotrophic lateral sclerosis (ALS) – a rare, progressive, fatal disease that damages the brain and spinal cord – had the highest rate of voluntary assisted dying. People with ALS accessed voluntary assisted dying at a rate nearly seven times higher than people with cancer.

Meanwhile, cancer patients were four times more likely to access voluntary assisted dying than those with lung disease, and ten times more likely than those with heart disease.

What Does This Tell Us?

Cancer and ALS, which appear to be the main reasons people access voluntary assisted dying, have very little in common. But both often cause a more rapid decline in health and a greater perceived loss of dignity than other conditions.

Our findings align with other research that shows people usually request voluntary assisted dying because they have lost autonomy, dignity, or the ability to do things that are meaningful to them.

Critics of voluntary assisted dying worry people might be pressured into choosing this option. One of the concerns is that people will opt for assisted dying because of a lack of palliative care. This refers to specialised care and treatment that helps people with serious life-limiting conditions live comfortably and fully.

Interestingly, while people with lung or heart conditions use palliative care less than those with cancer, our study found they are less likely to access voluntary assisted dying. If voluntary assisted dying was driven by poor access to services, we’d expect higher rates for heart and lung disease.

Similarly, recent data from Canada and Australia show most people who request voluntary assisted dying receive palliative care.

Where To From Here?

Our study doesn’t rule out that a range of factors, including poor access to services, may influence some cases. But it helps clarify common misconceptions about what drives voluntary assisted dying.

Further research should look at why cancer and ALS make up the largest proportion of cases. If voluntary assisted dying is primarily about swift decline and loss of dignity, we must focus on new ways to support patients facing these challenges.

And while voluntary assisted dying can promote autonomy and compassion, allowing people who are suffering to choose when and how they die, our findings don’t diminish the importance of protecting vulnerable people.

Robust safeguards to ensure decisions are voluntary and only eligible people have access, as well as high-quality palliative and supportive care, are essential in any voluntary assisted dying framework.

This article was developed with input from Brandon Heidinger, a medical student at the University of Western Ontario.

(Authors: Eliana Close, Senior Research Fellow, Australian Centre for Health Law Research, Queensland University of Technology and James Downar, Head and Professor, Division of Palliative Care, Department of Medicine, L’Université d’Ottawa/University of Ottawa)

(Disclosure Statement: Eliana Close has received funding from the Commonwealth government for research and training about the law, policy and practice relating to end-of-life care (Australian Department of Health, End of Life Law for Clinicians). In relation to voluntary assisted dying, she is employed on an Australian Research Council Future Fellowship project funded by the Australian government (Enhancing End-of-Life Decision-Making: Optimal Regulation of Voluntary Assisted Dying, Chief Investigator, Professor Ben White). She has also been employed on projects funded by the Victorian, Western Australian, and Queensland governments to design and provide the legislatively mandated training for health practitioners involved in voluntary assisted dying in those states. James Downar has received consulting fees from Joule, Inc. to develop educational material relevant to Medical Assistance in Dying. He is a former unpaid chair of the Clinical Advisory Council for Dying with Dignity Canada, a group advocating for the legalization of Medical Assistance in Dying in Canada)

This article is republished from The Conversation under a Creative Commons license. Read the original article.
 

Russia has developed an mRNA vaccine against cancer, Russian news agency TASS has reported. The vaccine will be distributed to cancer patients for free, General Director of the Radiology Medical Research Center of the Russian Ministry of Health, Andrey Kaprin, told Radio Rossiya.

The vaccine has been developed in collaboration with several research centers and is expected to be released for public use by early 2025.

The vaccine’s pre-clinical trials had shown that it suppresses tumor development and potential metastases, Director of the Gamaleya National Research Center for Epidemiology and Microbiology Alexander Gintsburg told TASS.

What Is An mRNA Vaccine?

mRNA or messenger-RNA vaccines use specific parts of the infectious agent like its protein, sugar, or coating. mRNA vaccine gives a message to our cells to make a protein or even just a piece of a protein which are like those of the virus. The protein then triggers an immune response inside our bodies.

Can AI Help Generate Personalised Cancer Vaccines?

Earlier, in an interview with TASS, Mr Gintsburg had said that the use of artificial neural networks could bring down the duration of computing required to create a personalized cancer vaccine to less an hour.

“Now it takes quite long to build [personalized vaccines] because computing of how a vaccine, or customized mRNA, should look like uses matrix methods, in mathematical terms. We have involved the Ivannikov Institute which will rely on AI in doing this math, namely neural network computing where these procedures should take about half an hour to an hour,” Russia’s vaccine chief said.

London:

UK claimants on Wednesday announced legal action against US pharmaceutical and cosmetics giant Johnson & Johnson, alleging that women diagnosed with cancers were exposed to asbestos in the company’s talcum powder.

J&J risks UK court action for the first time over the allegations, having faced a series of similar lawsuits in North America.

KP law, the firm representing about 2,000 claimants, said “women who have been diagnosed with life-changing and life-limiting cancers were exposed to asbestos contained within the company’s talcum powder”.

In response Erik Haas, J&J’s worldwide vice president of litigation, said “Johnson & Johnson takes the issue of talc safety incredibly seriously and always has”.

Haas added that J&J’s own analysis found an absence of asbestos contamination in its products and said “independent science makes clear that talc is not associated with the risk of ovarian cancer nor mesothelioma”.

J&J has until the end of the year to respond to a letter sent on behalf of KP Law’s clients, following which documents will be filed in the UK’s High Court.

The law firm is representing predominantly women regarding the case, and says it has been contacted by thousands more, adding that some have died of their cancers.

Lawyers claim that the US-based corporation knew “as early as the 1970s that asbestos in its talc products was dangerous but failed to warn consumers and carried on producing and selling the products in the UK until as recently as 2022”.

J&J said that Kenvue, its former consumer-health division that it separated out in 2023, is responsible for “any alleged talc liability that arises outside the US or Canada”.

Kenvue did not immediately respond to a request for comment from AFP .  

SETTLED CLAIMS

However, in September, J&J increased its offer to settle talc claims relating to ovarian cancer in the US to around $8 billion to be paid over 25 years.

Earlier this year, the company agreed to pay $700 million to settle allegations it misled customers about the safety of its talcum-based power products in North America.

The company did not admit wrongdoing in its settlement but withdrew the product from the North American market in 2020.

The World Health Organization’s cancer agency in July classified talc as “probably carcinogenic” for humans.

A summary of studies published in 2020 covering 250,000 women in the United States did not find a statistical link between the use of talc on the genitals and the risk of ovarian cancer.
 

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

New Delhi:

A high profile global initiative to tackle cancer called the ‘Cancer Moonshot’ will be announced on the sidelines of the Quad Summit. Ahead of that an India cancer specific cancer genome atlas has been released. Till date, all cancer treatments were based on western datasets, say the experts who made the cancer atlas. This had led to complications. India has the third-highest number of cancer cases after the US and China.

The release of the Cancer Genome Atlas of India is timely since according to estimates by the Indian Council of Medical Research (ICMR), in India, the incidence of cancer cases is likely to increase from 1.46 million in 2022 to 1.57 million in 2025.

The Quad Summit to be held in Philadelphia will be attended by Prime Minister Narendra Modi, US President Joe Biden, Australian Prime Minister Anthony Albanese and Japanese Prime Minister Fumio Kishida. While global security will be high on the agenda, the menace of cancer is also not being ignored.

Cancer Moonshot is a special programme spearheaded by Mr Biden and the US First Lady. The White House says it is building a world where the word cancer loses its power, a diagnosis isn’t a death sentence, and to prevent cancer before it starts.

“We catch cancer early so people live longer and healthier lives, and patients and families don’t have to navigate their cancer journey alone. To prevent more than four million cancer deaths by 2047 and to improve the experience of people who are touched by cancer,” it said.

The Indian Cancer Genome Atlas (ICGA) is aimed at transforming cancer research and treatment for the Indian population. Historically, cancer treatments in India have been based on western data sets. However, cancers in Indian patients can differ significantly at the molecular level.

The ICGA’s mission is to create Indian-specific datasets to help researchers and clinicians develop personalised treatment protocols. This new open-access portal represents a monumental step in revolutionising cancer research, specifically for Indian patients.

Currently, the platform consists of data from 50 breast cancer patients, with plans to expand to over 500 patients in the coming year. Experts suggest that in 2022, India reported 1.92 lakh cases of breast cancer, constituting 26.6 per cent of all cancer cases, along with 98,337 deaths, accounting for 13.7 per cent of all cancer-related fatalities.

The Indian Cancer Genome Atlas (ICGA) is a national initiative focused on mapping cancers across India, supported by a foundation formed by over 50 clinicians, researchers, and data analysts. Its mission is to enhance cancer diagnosis and treatment for Indian patients and contribute to the global understanding of cancer biology.

The open access dataset will drive transformative breakthroughs in cancer treatment, said professor Shekhar C Mande, former Director General, Council of Scientific and Industrial Research (CSIR) and currently senior professor at Savitribai Phule Pune University.

“Making this invaluable cancer data publicly accessible marks a pivotal step in accelerating scientific discoveries and enhancing patient outcomes. By openly sharing this data, we are empowering researchers, clinicians, and innovators to collaborate, explore new frontiers, and drive transformative breakthroughs in cancer treatment,” Mr Mande said.

India uniquely has a high burden of cancers related to the digestive system; oral and lung cancer, mostly related to tobacco use; cervical cancer is increasing and breast cancer are all on the rise.

New York:

Cancer cells rarely begin stealthily. Quite the contrary, they alert the immune system to their presence by displaying chemical red flags on their membranes. When detected, the body’s defences can swoop in and destroy renegade cells before they can do significant damage. Lipids, fatty molecules traditionally thought to be largely a fuel supply for developing tumours, are at the heart of this early detection system.

However, a new study in Nature shows that one specific lipid type is essential for cancer immune evasion — so much so that certain cancer cells cannot reproduce without it. The findings validate long-held assumptions that not only is this lipid a crucial factor in cancer biology (and thus a key therapeutic target).

“Cancer cells are altering how this lipid is metabolized, which in turn distorts the ‘eat me’ signals that malignant cells usually produce,” says first author Mariluz Soula, a former graduate student in the laboratory of Kivanc Birsoy, and now a scientist Lime Therapeutics. “This paints a very different picture of the role lipids play in cancer growth.”

Scientists have long known that cancer cells alter lipid metabolism, but it was generally assumed that cancer cells were gobbling up these lipids for energy–consuming the fatty molecules to help the tumor grow and spread far beyond that of healthy cells.

“We knew from the literature that elevated lipid levels correlate with severity of cancer growth and metastasis, but it was unclear how,” Soula says. The Birsoy lab, in conjunction with the laboratory of Gabriel D. Victoria, set out to answer this question by screening the genes involved in this process. They then implanted a series of cancer cells, each missing a different such gene, into mice with and without immune systems–thereby revealing which lipids a cancer cannot live without.

The result: so-called “sphingolipids.” Discovered in the late 1800s by German chemist Johann Ludwig Wilhelm Thudichum, sphingolipids were named after the enigmatic Sphinx of Greek lore because of their puzzling structure and function. Two centuries later, sphingolipids are less of a mystery. “We know that sphingolipids aren’t really used for energy,” Soula says. “They’re mainly in the cell membrane to create scaffolding for signaling proteins.”

This finding raised an intriguing possibility. Was lipid metabolism in cancer cells really just the story of hungry cells trying to consume more energy? Or was it a key part of the cancer cell’s efforts to subtly manipulate cell signaling and dodge the immune system?

To test how sphingolipids were driving cancer growth, the team turned to an FDA-approved drug used to treat Gaucher disease–a genetic disorder characterized by an impaired ability to break down lipids. The drug essentially blocks glycosphingolipid synthesis, and the team found that this impaired tumor growth in pancreatic, lung, and colorectal cancer models.

They also found that depleting glycosphingolipids prevented the formation of the “lipid nanodomains” that bunch signalizing molecules together on the membrane, impacting the cell’s surface receptors on the cell surface in a way that made them more sensitive to an immune response. These findings suggest that cancer cells hoard glycosphingolipids in order to obscure inflammatory signals, and that disrupting glycosphingolipid production can leave cancer cells vulnerable to the immune system.

“Everyone thought of elevated lipid levels as an energy source for cancer cells to consume,” Soula says. “We discovered that it’s far more nuanced. Lipids are not just fuel, but a protection mechanism for cancer cells that modulates how they communicate with the immune system.”

Future work will determine whether this holds true for multiple cancers. The team tested a variety of types, but found this mechanism at work in KRAS-dependent cancers (so named for the mutated oncogene that drives them). Still, the initial results could have significant clinical impact, given how aggressive many KRAS-dependent cancers, such as pancreatic cancer, tend to be. Based on their findings, the team suggests that drug and dietary interventions that stunt sphingolipid production may help increase the efficacy of existing immunotherapies.

“Diets may impact many aspects of cancer biology,” Birsoy says. “We believe modulating dietary lipids may be an interesting avenue to target cancer cells’ ability to evade immune cells.”

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

In the last few decades, scientists have finally learned to harness the immune system to successfully treat cancer. Image for Representation.
| Photo Credit: Freepik

In the last few decades, scientists have finally learned to harness the immune system to successfully treat cancer. Although doctors often use immunotherapy drugs, another type of treatment uses patient’s cells to treat their own cancers.

Car-T therapy, short for “chimeric antigen receptor T-cell”, is a cutting-edge treatment that reprogrammes a patient’s immune cells to fight their cancer. This innovative approach involves taking T-cells, a type of white blood cell that plays a crucial role in the immune system, from a patient and modifying them in a laboratory to better recognise and attack cancer cells.

These enhanced T-cells are then multiplied and infused back into the patient, where they seek out and destroy cancer cells. Lots of data shows that in difficult-to-treat lymphomas, a type of cancer, patients can do so well.

In November 2023, the US Food and Drug Administration (FDA) announced an investigation into this celebrated cancer treatment. They were looking into whether Car-T therapy might be causing new cancers in some patients who had undergone the treatment. This was a significant concern given the therapy’s reputation as a revolutionary cancer-fighting strategy.

Initially, the FDA mentioned that it had observed 20 cases where patients developed new immune-cell cancers, such as lymphomas or leukaemias, which are types of blood cell cancer, after receiving Car-T therapy. This prompted questions about who these patients were, how many such cases existed and what other treatments they might have received before Car-T therapy.

By March 2024, the FDA had documented 33 such cases among around 30,000 treated patients. Consequently, all Car-T therapies now carry a boxed warning about the potential risk of developing secondary cancers. The European Medicines Agency also started its own investigation into the matter.

Despite these concerns, it is still unclear whether the new cancers are directly caused by the Car-T cells or whether other factors are involved. It is also important to note that these cancers are very rare – as data published this month shows.

Many cancer treatments come with a risk of secondary malignancies and, of course, the cancer returning. And patients receiving Car-T therapy often have had several other treatments that could also contribute to the risk. Researchers are now working to determine if Car-T therapy is a contributing factor or the primary cause of these new cancers.

Car-T therapy was initially used for patients with no other treatment options, but it has since been approved as a second-line treatment for certain types of blood cancers, like lymphoma and multiple myeloma. Scientists are also exploring its potential for treating solid tumours including hard to treat brain cancers, autoimmune diseases, ageing, HIV and other conditions.

The process of creating Car-T cells involves using viruses to insert new genetic material into T-cells. These viruses, called retroviruses, are engineered to carry the gene for a chimeric antigen receptor (Car) into the T-cells.

Massive benefits

While these retroviruses are modified to be safe, there is always a risk that the new genetic material could disrupt other important genes and potentially lead to cancer – a phenomenon known as “insertional mutagenesis”. This means new genetic material is added to a cell.

This risk isn’t new. About 20 years ago, gene therapy treatments for severe combined immunodeficiency syndrome using similar retroviruses led to leukaemia in some patients. As a result, scientists have worked to improve the safety of these viral vectors. The FDA now requires thorough testing to ensure that the viruses used in Car-T therapy cannot replicate and cause harm.

Despite these findings, the most important thing to emphasise is that secondary cancers remain rare and these cell therapies can have massive benefits in very sick people.

The new review of patients treated with Car-T therapies at various centres found that only a small percentage developed secondary cancers, and most were not the type directly linked to the Car-T treatment. This suggests that while there is a risk, it is relatively low compared to the immediate threat posed by the patient’s existing cancer.

Medical professionals now inform patients about the potential but rare risk of secondary cancers when discussing Car-T therapy. For most patients, especially those with advanced cancers, the potential benefits of Car-T therapy far outweigh these risks.

As mentioned, Car-T therapy is also being investigated for other applications beyond cancer. For instance, it has shown promise in treating autoimmune diseases such as lupus and even in preventing organ transplant rejection. The potential uses for Car-T cells are continually expanding, offering hope for treating a wide range of diseases.

Ultimately, while the risk of secondary cancers from Car-T therapy is a serious consideration, the benefits for many patients are significant and far outweigh this small risk. Research will continue to refine these treatments and improve their safety.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

New Delhi:

Poor lifestyle choices with regular consumption of ultra-processed food, and a sedentary lifestyle are increasing cancer cases among people under 40 years of age in India, said doctors on Sunday.

Several factors are contributing to the rise in cancer cases among younger people in India.

One of the primary reasons is increased consumption of processed foods, tobacco, and alcohol, sedentary lifestyles, obesity, and stress.

Environmental pollution is another critical factor.

India’s cities are plagued by high levels of pollution, which has been linked to various types of cancer.

Air and water pollution expose individuals to carcinogenic substances, significantly increasing their cancer risk.

“Ultra-processed foods and sedentary lifestyles are emerging as significant contributors to the rising cancer rates among young Indians.

“The high intake of these foods, laden with unhealthy additives, combined with physical inactivity, is creating a health crisis,” Dr. Rahul Bhargava, Director and head of the Department of Haematology and BMT at Fortis Memorial Research Institute told IANS.

“It’s imperative to adopt healthier dietary habits and an active lifestyle to curb this alarming trend,” he added.

According to a recent study by Cancer Mukt Bharat Foundation, a Delhi-based non-profit foundation, 20 per cent of cancer cases in India are now being diagnosed in people below 40 years of age.

The study shows that men constitute 60 per cent of these young cancer patients, while women make up the remaining 40 per cent.

The gender disparity may be due to higher rates of tobacco use, occupational exposure, and lifestyle choices among men in India.

“In our country, escalating rates of obesity, change in dietary habits, specifically the increase in consumption of ultra-processed food, and sedentary lifestyles are associated with higher cancer rates,” said Dr. Ashish Gupta, principal investigator and senior oncologist at Unique Hospital Cancer Center, Delhi, told IANS.

The doctors called for the urgent need for lifestyle interventions to combat the rising cancer rates among young Indians. Dr. Ashish, also heading Cancer Mukt Bharat Campaign in India, emphasised the importance of a “combined effort from the government, healthcare professionals, and the community to tackle the rising cancer rates among young adults”.

“Policies promoting clean air and water, regular physical activity, and access to nutritious food must be prioritised. Additionally, we must invest in better healthcare infrastructure to ensure timely diagnosis and treatment,” he said.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

Mumbai:

Jet Airways founder Naresh Goyal’s wife Anita Goyal passed away on Thursday morning after suffering from the final stage of cancer.

Anita Goyal is survived by her husband and two children, Namrata and Nivaan Goyal.

According to reports, she passed away around 3 a.m. and Naresh Goyal was at their Mumbai residence.

As executive vice president, Anita was part of operations at the company.

Naresh Goyal, himself suffering from multiple health issues, sought interim bail from the Bombay High Court earlier this month on humanitarian grounds to be with his wife.

He was nabbed on September 1, 2023, in connection with a money-laundering case.

He is currently in judicial custody and lodged at the Arthur Road Central Jail (ARCJ).

In the bail plea, Naresh Goyal had claimed that he did not siphon off loan amounts for personal benefits, as alleged by the ED in the Canara Bank loan of Rs 538.62 crore given to the Jet Airways group.

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)